Login / Signup

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.

Relinde I Y LieverseEvert J Van LimbergenCary J G OberijeEsther G C TroostSine R HadrupAnne-Marie C DingemansLizza E L HendriksFranziska EckertCrispin HileyChristophe DoomsYolande LievensMonique C de JongJohan BussinkXavier GeetsVincenzo ValentiniGiuliano EliaDario NeriCharlotte BillietAmir AbdollahiDavid PasquierPierre BoisselierAla YarominaDirk De RuysscherLudwig J DuboisPhilippe Lambin
Published in: BMC cancer (2020)
ImmunoSABR Protocol Code: NL67629.068.18; EudraCT: 2018-002583-11; Clinicaltrials.gov: NCT03705403; ISRCTN ID: ISRCTN49817477; Date of registration: 03-April-2019.
Keyphrases